STAT3 and non-small cell lung carcinoma: Accordingly, increased STAT3 activity is observed in tumors of gefitinib-unresponsive NSCLC patients, while inhibition of STAT3 via siRNA-mediated interference in gefitinib-resistant NSCLC cells restores drug sensitivity and promotes apoptosis [264].